Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzomenib maintenance after allogeneic transplant for menin-sensitive AML
ACTRN12626000019303Phase 2Not yet recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) comparing Enzomenib maintenance with Placebo (2 arms). Primary endpoint: Relapse-free survival. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
enzomenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ACTRN12626000019303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000019303.